p.103 抽出テキスト
742. Scherrenberg M, Wilhelm M, Hansen D, Völler H, Cornelissen V, Frederix I, et al. The future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic from the secondary prevention and rehabilitation section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;28:524–540. https://doi.org/10.1177/ 2047487320939671 743. Huang K, Liu W, He D, Huang B, Xiao D, Peng Y, et al. Telehealth interventions versus center-based cardiac rehabilitation of coronary artery disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:959–971. https://doi.org/10.1177/ 2047487314561168 744. Wolf A, Vella R, Fors A. The impact of person-centred care on patients’ care experiences in relation to educational level after acute coronary syndrome: secondary outcome analysis of a randomised controlled trial. Eur J Cardiovasc Nurs 2019;18:299–308. https://doi.org/10.1177/1474515118821242 745. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. Am J Med Sci 2016;351:387–399. https://doi.org/10.1016/j. amjms.2016.01.010 746. Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail: addressing psychological risk factors of nonadherence. Curr Opin Psychiatry 2017;30:326–333. https://doi.org/10.1097/yco.0000000000000345 747. Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int J Pharm Pract 2019;27:223–231. https://doi.org/10.1111/ijpp.12491 748. Seabury SA, Dougherty JS, Sullivan J. Medication adherence as a measure of the quality of care provided by physicians. Am J Manag Care 2019;25:78–83. 749. Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, et al. How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2022;30:149–166. https://doi.org/10.1093/eurjpc/zwac204 750. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014;64:2071–2082. https://doi.org/10.1016/j.jacc.2014.08.021 751. Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2019;105:42–48. https://doi.org/10.1136/heartjnl-2018- 313108 752. Castellano JM, Fuster V, Jennings C, Prescott E, Bueno H. Role of the polypill for secondary prevention in ischaemic heart disease. Eur J Prev Cardiol 2017;24:44–51. https:// doi.org/10.1177/2047487317707324 753. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 967–977. https://doi.org/10.1056/NEJMoa2208275 754. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev 2018;6:CD012675. https://doi.org/10.1002/ 14651858.CD012675.pub2 755. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The costeffectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. Eur J Health Econ 2013;14:789–797. https://doi.org/10.1007/s10198-012- 0424-5 756. Gandapur Y, Kianoush S, Kelli HM, Misra S, Urrea B, Blaha MJ, et al. The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes 2016;2:237–244. https://doi. org/10.1093/ehjqcco/qcw018 757. Fortuna RJ, Nagel AK, Rocco TA, Legette-Sobers S, Quigley DD. Patient experience with care and its association with adherence to hypertension medications. Am J Hypertens 2018;31:340–345. https://doi.org/10.1093/ajh/hpx200 758. Keenan J. Improving adherence to medication for secondary cardiovascular disease prevention. Eur J Prev Cardiol 2017;24:29–35. https://doi.org/10.1177/ 2047487317708145 759. Geidl W, Schlesinger S, Mino E, Miranda L, Pfeifer K. Dose-response relationship between physical activity and mortality in adults with noncommunicable diseases: a systematic review and meta-analysis of prospective observational studies. Int J Behav Nutr Phys Act 2020;17:109. https://doi.org/10.1186/s12966-020-01007-5 760. Ekblom O, Ek A, Cider Å, Hambraeus K, Börjesson M. Increased physical activity postmyocardial infarction is related to reduced mortality: results from the SWEDEHEART registry. J Am Heart Assoc 2018;7:e010108. https://doi.org/10.1161/jaha.118.010108 761. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 2022;399:1876–1885. https://doi.org/10.1016/s0140-6736(22)00122-2 762. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779–785. https://doi.org/10.1161/01.cir.99.6.779 763. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. https://doi.org/10.1001/jama.290.1.86 764. Chow CK, Jolly S, Rao-Melacini P, Fox KAA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750–758. https://doi.org/10.1161/ circulationaha.109.891523 765. United States Public Health Service Office of the Surgeon General. Smoking Cessation: A Report of the Surgeon General. In: US Department of Health and Human Services; 2020. 766. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/ AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/ AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016;134: e123–e155. https://doi.org/10.1161/cir.0000000000000404 767. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 2013:CD009329. https://doi.org/10.1002/14651858.CD009329.pub2 768. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation 2016;133:21–30. https://doi.org/10.1161/circulationaha.115.019634 769. Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2016;5:e002849. https://doi.org/10.1161/jaha.115.002849 770. Windle SB, Dehghani P, Roy N, Old W, Grondin FR, Bata I, et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ 2018;190:E347–E354. https://doi. org/10.1503/cmaj.170377 771. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;28:1552–1566. https://doi.org/10.1177/2047487320941993 772. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34. https://doi.org/10.1056/NEJMoa1800389 773. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391: 1513–1523. https://doi.org/10.1016/s0140-6736(18)30134-x 774. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014;349:g4164. https://doi.org/10.1136/bmj.g4164 775. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet 2019;393:1831–1842. https://doi.org/10.1016/ s0140-6736(18)31772-0 776. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ 2019;366:l4570. https://doi.org/10.1136/bmj.l4570 777. Patterson R, McNamara E, Tainio M, de Sá TH, Smith AD, Sharp SJ, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol 2018;33:811–829. https://doi.org/10.1007/s10654-018-0380-1 778. WHO Guidelines Review Committee. WHO Guidelines on Physical Activity and Sedentary Behaviour. World Health Organization, 2020. 779. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2022;29:230–245. https://doi.org/10.1093/eurjpc/zwab007 780. De Schutter A, Kachur S, Lavie CJ, Menezes A, Shum KK, Bangalore S, et al. Cardiac rehabilitation fitness changes and subsequent survival. Eur Heart J Qual Care Clin Outcomes 2018;4:173–179. https://doi.org/10.1093/ehjqcco/qcy018 781. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011; 2011:Cd008012. https://doi.org/10.1002/14651858.CD008012.pub3 Downloaded from academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 07 October 2026